CoChat

Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review

Open access
Roeder, F., Meldolesi, E., Gerum, S., Valentini, V., Rödel, C. · 2020 · Radiation Oncology
Cited by 77

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The role of radiation therapy in the treatment of (colo)-rectal cancer has changed dramatically over the past decades. Introduced with the aim of reducing the high rates of local recurrences after conventional surgery, major developments in imaging, surgical technique, systemic therapy and radiation delivery have now created a much more complex environment leading to a more personalized approach. Functional aspects including reduction of acute or late treatment-related side effects, sphincter or even organ-preservation and the unsolved problem of still high distant failure rates have become more important while local recurrence rates can be kept low in the vast majority of patients. This review summarizes the actual role of radiation therapy in different subgroups of patients with rectal cancer, including the current standard approach in different subgroups as well as recent developments focusing on neoadjuvant treatment intensification and/or non-operative treatment approaches aiming at organ-preservation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13014-020-01695-0

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 165

  1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87. https://doi.org/10.1016/j.ejca.2018.07.005. · DOI · Paper page
  2. Hall WH. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50. https://doi.org/10.1001/jama.264.11.1444. · doi:10.1001/jama.264.11.1444 · Paper page
  3. Marsh PJ, James RD, Schofield PF. Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma—results of a prospective, randomized trial. Dis Colon Rectum. 1994;37:1205–14. https://doi.org/10.1007/BF02257783. · DOI · Paper page
  4. Martling A, Holm T, Rutqvist LE, Johansson H, Moran BJ, Heald RJ, et al. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg. 2005;92:225–9. https://doi.org/10.1002/bjs.4834. · DOI · Paper page
  5. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20. https://doi.org/10.1016/S0140-6736(09)60484-0. · DOI · Paper page
  6. Bipat S, Glas AS, Slors FJM, Zwinderman AH, Bossuyt PMM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology. 2004;232:773–83. https://doi.org/10.1148/radiol.2323031368. · DOI · Paper page
  7. Burton S, Brown G, Daniels I, Norman A, Swift I, Abulafi M, et al. MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: treatment with radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:445–51. https://doi.org/10.1016/j.ijrobp.2005.12.027. · DOI
  8. Brown G, Richards CJ, Newcombe RG, Dallimore NS, Radcliffe AG, Carey DP, et al. Rectal carcinoma: thin-section MR imaging for staging in 28 patients. Radiology. 1999;211:215–22. https://doi.org/10.1148/radiology.211.1.r99ap35215. · DOI · Paper page
  9. Brown G, Kirkham A, Williams GT, Bourne M, Radcliffe AG, Sayman J, et al. High-resolution MRI of the anatomy important in total mesorectal excision of the rectum. Am J Roentgenol. 2004;182:431–9. https://doi.org/10.2214/ajr.182.2.1820431. · doi:10.2214/ajr.182.2.1820431
  10. Beets-Tan RGH. Pretreatment MRI of lymph nodes in rectal cancer: an opinion-based review. Colorectal Dis. 2013;15:781–4. https://doi.org/10.1111/codi.12300. · DOI
  11. Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol (Madr). 2008;47:20–31. https://doi.org/10.1080/02841860701697720. · DOI · Paper page
  12. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33. https://doi.org/10.1200/JCO.2011.40.1836. · DOI · Paper page
  13. Mullen TD, Kim EY, Apisarnthanarax S. Short-course radiation therapy versus long-course chemoradiation in the neoadjuvant treatment of locally advanced rectal cancer: new insights from randomized trials. Curr Colorectal Cancer Rep. 2017;13:165–74. https://doi.org/10.1007/s11888-017-0359-4. · DOI
  14. Ciseł B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30:1298–303. https://doi.org/10.1093/annonc/mdz186. · DOI · Paper page
  15. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol. 2012;30:3827–33. https://doi.org/10.1200/JCO.2012.42.9597. · DOI · Paper page
  16. Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18:336–46. https://doi.org/10.1016/S1470-2045(17)30086-4. · DOI · Paper page
  17. Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34:3773–80. https://doi.org/10.1200/JCO.2016.67.6049. · DOI · Paper page
  18. Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicenter, phase 2 trial. Lancet Oncol. 2015;16:957–66. · DOI · Paper page
  19. Fokas E, Allgäuer M, Polat B, et al. Randomized phase II trial of chemoradiotherapyy plus induction or consolodaation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37:3212–22. · DOI · Paper page
  20. Glynne-Jones R. TNT in rectal cancer may not be the new testament? EClinicalMed. 2019;16:4–5. https://doi.org/10.1016/j.eclinm.2019.10.004. · doi:10.1016/j.eclinm.2019.10.004
  21. Bujko K, Glimelius B, Valentini V, Michalski W, Spalek M. Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: a meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin. Eur J Surg Oncol. 2015;41:713–23. https://doi.org/10.1016/j.ejso.2015.03.233. · DOI
  22. Rödel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cacer (the German CAO/ARO/AIO-04 study): final results oft eh multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:979–89. · DOI · Paper page
  23. O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and Oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from national surgical adjuvant breast and bowel projevt trial R-04. J Clin Oncol. 2014;32:1927–34. · DOI · Paper page
  24. Haustermans K, Schmoll HJ, Price T, et al. First results of the PETACC-6 randomized phase III trial in locally advanced rectal cancer. Radiother Oncol. 2014;111(suppl 1):96 ((abstract)). · doi:10.1016/s0167-8140(15)30355-8
  25. Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicentre, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016;34:3300–7. · DOI · Paper page
  26. Maas M, Nelemans PJ, Valentini V, et al. Long term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44. · DOI · Paper page
  27. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558–65. · DOI · Paper page
  28. Deng Y, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019;37:3223–33. · DOI · Paper page
  29. Gustavsson B, Carlsson G, Machover D, et al. A rewvies of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorect Cancer. 2015;14:1–10. · DOI · Paper page
  30. Mehta VK, Cho C, Ford JM, et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and wekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys. 2003;55:132–7. · DOI
  31. Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol. 2005;23:1350–7. · DOI
  32. Klautke G, Feyerherd P, Ludwig K, et al. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer. 2005;92:1215–20. · DOI
  33. Klautke G, Küchenmeister U, Foitzik T, et al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer. 2006;94:976–81. · DOI
  34. Navarro M, Dotor E, Rivera F, et al. A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66:201–5. · DOI
  35. Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (Capiri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer. 2007;96:912–7. · DOI
  36. Glynne-Jones R, Falk S, Maughan TS, et al. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a colorectal clinical oncology group study. Br J Cancer. 2007;96:551–8. · DOI
  37. Shin SJ, Kim NK, Keum KC, et al. Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. Radiother Oncol. 2010;95:303–7. · DOI
  38. Gollins S, Myint AS, Haylock B, et al. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes. J Clin Oncol. 2011;29:1042–9. · DOI
  39. Sato T, Ozawa H, Hatate K, et al. A phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. Int J Radiat Oncol Biol Phys. 2011;79:677–83. · DOI
  40. Hong YS, Kim DY, Lim SB, et al. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a phase II study. Int J Radiat Oncol Biol Phys. 2011;79:1171–8. · DOI
  41. Wong SJ, Winter KW, Meropol NJ, et al. RTOG0247: a randomized phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiation therapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82:1367–75. · DOI
  42. Wong SJ, Moughan J, Meropol NJ, et al. Efficacy endpoints of RTOG 0247: a randomized phase II study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2015;91:116–23. · doi:10.1016/j.ijrobp.2014.09.031
  43. Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 2006;24:650–5. · DOI · Paper page
  44. Mohiuddin M, Paulus R, Mitchell E, et al. 5-year updated results of RTOG-0012 randomized phase II study of neoadjuvant combined modality chemoradiation for distal rectal cancer. Int J Radiat Oncol Biol Phys. 2013;86:523–8. · DOI
  45. Zhu J, Li X, Shen Y, et al. Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer. Radiother Oncol. 2018;129:143–8. · DOI
  46. Guan Y, Shen Y, Li C, et al. An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjvant radiotherapy for locally advanced rectal cancer with UGT1A!*1*1 genotype. Ther Adv Gastroenterol. 2019;12:1–11. · doi:10.1177/1756284819852293
  47. Zhang Z, Sun X, Liu A, et al. A multicenter randomized phase III trial of capecitabine with or withour irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare). J Clin Oncol. 2019;37(1):3510 ((abstract)). · doi:10.1200/jco.2019.37.15_suppl.3510
  48. Wang J, Fan J, Li C, et al. The impact of chemotherapy completion on the efficacy of irinotecan in the preoperative chemoradiatiotherapy of locally advanced rectal cancer: an expanded analysis of the CinClare phase III trial. Clin Colorectal Cancer. 2020;19:e58–69. · doi:10.1016/j.clcc.2020.01.004
  49. Crane CH, Eng C, Feig BW, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76:824–30. · DOI · Paper page
  50. Willett CG, Duda DG, Ankukiewicz M, et al. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist. 2010;15:845–51. · DOI
  51. Kourkourakis MI, Giatromanolaki A, Tsoutsou P, et al. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HYPOARC) for rectal cancer: a phase II study. Int J Radiat Oncol Biol Phys. 2011;80:492–8. · DOI
  52. Liang JT, Lai HS, Cheng KW. Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy wih bevacizumab plus FOLFOX. Surg Endosc. 2011;25:305–8. · DOI
  53. Velenik V, Ocvirk J, Music M, et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol. 2011;6:105. · DOI
  54. di Petrillo T, Pricolo V, Lagares-Garcia J, et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82:124–9. · DOI
  55. Gasparini G, Torino F, Ueno T, et al. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis. 2012;15:141–50. · DOI
  56. Resch G, De Vries A, Öfner D, et al. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer—a two stage phase II clinical trial. Radiother Oncol. 2012;102:10–3. · DOI
  57. Kennecke H, Berry S, Wong R, et al. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patiets with locally advanced or low rectal cancer: a phase II trial. Eur J Cancer. 2012;48:37–45. · DOI
  58. Spigel DR, Bendell JC, McCleod M, et al. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin Colorect Cancer. 2012;11:45–52. · DOI
  59. Landry JC, Feng Y, Cohen SJ, et al. Phase II study of preoperative radiation with concurrent capecitabine, oxaliplatin and bevacizumab followed by surgery and postoperative 5-FU, Leucovorine, Oxaliplatin (FOLFOX) and bevacizumab in patients with locally dvanced rectal cancer: ECOG 3204. Cancer. 2013;119:1521–7. · DOI
  60. Dellas K, Höhler T, Resse T, et al. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol. 2013;8:90. · DOI
  61. Wang CC, Liang JT, Tsai CL, et al. Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity. World J Surg Oncol. 2014;12:329. · doi:10.1186/1477-7819-12-329
  62. Borg C, Andre T, Mantion G, et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized noncomparative phase II study. Ann Oncol. 2014a;25:2205–10. · DOI
  63. Garcia M, Martinez-Villacampa M, Santos C, et al. Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer. BMC Cancer. 2015;15:59. · DOI
  64. Sadahiro S, Suzuku T, Tanaka A, et al. Phase II study of preoperative concurrent chemoradiotherapy with S-1 plus bevacizumab for locally advanced resectable rectal adenocarcinoma. Oncology. 2015;88:49–56. · DOI
  65. Salazar R, Capdevilla J, Laquente B, et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer. 2015;15:60. · DOI
  66. Maeda K, Shibutani M, Otani H, et al. Neoadjuvant Radiotherapy with capecitabine plus bevacizumab for locally advanced lower rectal cancer: results of a single-institute phase II study. Anticancer Res. 2018;38:4193–7. · DOI
  67. Yu X, Wang QX, Xiao WW, et al. Neoadjuvant oxaliplatin and capecitabine combined with bevacizuab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study. Cancer Commun. 2018;38:24. · DOI
  68. Machiels JP, Sempoux C, Scalliet P, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients wih rectal cancer. Ann Oncol. 2007;18:738–44. · DOI
  69. Rödel C, Arnold D, Hipp M, et al. Phase I-II trial of cetuximab, capecitabine, oxalipaltin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:1081–6. · DOI
  70. Valentini V, de Paoli A, Gambacorta MA, et al. Infusional 5-fluorouracil an ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092). Int J Radiat Oncol Biol Phys. 2008;72:644–9. · DOI
  71. Bertolini F, Chiara S, Nebgala C, et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2009;73:466–72. · DOI
  72. Horisberger K, Treschl A, Mai S, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys. 2009;74:1487–93. · DOI
  73. Velenik V, Ocvirk J, Oblak I, Anderluh F. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol. 2010;36:244–50. · DOI
  74. Kim SY, Hong YS, Kim DY, et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study. Int J Radiat Oncol Biol Phys. 2011;81:677–83. · DOI
  75. Pinto C, di Fabio F, Maiello E, et al. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (STARPan/STAR-02 study). Ann Oncol. 2011;22:2424–30. · DOI
  76. Sun PL, Li B, Ye QF. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study. Int J Colorectal Dis. 2012;27:1325–32. · DOI
  77. Kim SY, Shim EK, Yeo HY, et al. KRAS mutations status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. Int J Radiat Oncol Biol Phys. 2013;85:201–7. · DOI
  78. Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total esorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30:1620–7. · DOI · Paper page
  79. Helbling D, Bodoky G, Gautschi O, et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol. 2013;24:718–25. · DOI
  80. Eisterer W, de Vries A, Öfner D, et al. Preoperative treatment with capecitabine, cetuximab, and radiotherapy for primary locally advanced rectal cancer—a phase II clinical trial. Anticancer Res. 2014;34:6767–74.
  81. Mardjuadi FI, Carrasco J, Coche JC, et al. Panitumumab as a radiosensitizing agents in KRAS wild-type locally advanced rectal cancer. Targ Oncol. 2015;10:375–83. · DOI
  82. Jin T, Zhu Y, Luo JL, et al. Prospective phase II trial of nimotizumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer. Int J Colorectal Dis. 2015;30:337–45. · DOI
  83. Bazarbashi S, Omar A, Aljubran A, et al. Pre-operative chemoradiotherapy using capecitabine and cetuximab followed by definitive surgery in patients with operable rectal cancer. Hematol Oncol Stem Cell Ther. 2016;9:147–53. · DOI
  84. Gollins S, West N, Sebag-Montefiori D, et al. Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. Br J Cancer. 2017;117:1286–94. · DOI
  85. Pinto C, Di Bisceglie M, di Fabio F, et al. Phase II study of preoperative treatment with external radiotherapy plus panitumumab in low-risk, locally advanced rectal cancer (RaP study/STAR-03). Oncologist. 2018;23:912–8. · DOI
  86. Valentini V, Coco C, Minsky BD, et al. Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + Oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:403–12. · DOI
  87. Stojanovic S, Popov I, Radosevic-Jelic L, et al. Preoperative Radiotherapy with capecitabine and mitomycin C in locally advanced rectal carcinoma. Cancer Chemother Pharmacol. 2011;68:787–93. · doi:10.1007/s00280-010-1469-8
  88. Jeong JH, Hong YS, Park Y, et al. Phase 1 Study of preoperative chemoradiation therapy with temozolomide and capecitabine in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2016;96:289–95. · DOI
  89. Jakobsen A, Mortensen JP, Bisgaard, , et al. A Cox-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II study. Int J Colorectal Dis. 2008;23:251–5. · DOI
  90. Debucquoy A, Roels S, Goethals L, et al. Double blind randomized phase II study with radiation + 5-fluorouracil +/- celecoxib for resectable rectal cancer. Radiother Oncol. 2009;93:273–8. · DOI
  91. Wang LW, Hsiao CF, Chen WT, et al. Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study. J Surg Oncol. 2014;109:580–5. · DOI
  92. O’Neil BH, Raftery L, Calvo BF, et al. A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clin Colorectal Cancer. 2010;9:119–25. · DOI
  93. Buijsen J, Lammering G, Jansen RL, et al. Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiother Oncol. 2013;107:184–8. · DOI
  94. Meyer J, Arriaga Y, Anandam J, et al. A phase I clinical trial of the phosphatidylserine-targeting antibody bavituximab in combination with radiation therapy and capecitabine in the preoperative treatment of rectal adenocarcinoma. Am J Clin Oncol. 2018;41:972–6. · DOI
  95. von Moos R, Koeberle D, Schacher S, et al. Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: a phase I/II trial (SAKK 41/08). Eur J Cancer. 2018;89:82–9. · DOI
  96. Kim R, Prithviraj GK, Shridhar R, et al. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. Radiother Oncol. 2016;118:382–6. · DOI
  97. Czito BG, Deming DA, Jameson GS, et al. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. Lancet Gastroenterol Hepatol. 2017;2:418–26. · DOI
  98. Bendell JC, Thompson D, Hemphill BM, et al. A phase 2 study of 5-fluorouracl (5-FU), Ziv-Aflibercept, and radiation for the preoperative and adjuvant treatment of patients with stage II/III rectal cancer. Cancer Invest. 2017;35:535–40. · DOI
  99. Appelt AL, Ploen J, Vogelius IR, et al. Radiation doe-response model for locally advanced rectal cancer after pre-operative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2013;85:74–80. · DOI · Paper page
  100. Meade PG, Blatchford GJ, Thorson AG, Christensen MA, Tement CA. Preoperative chemoradiation downstages locally advanced ultrasound-staged rectal cancer. Am J Surg. 1995;170:609–13. · doi:10.1016/s0002-9610(99)80026-9
  101. Movsas B, Hanlon AL, Lanciano R, et al. Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 1998;42:43–50. · doi:10.1016/s0360-3016(98)00172-2
  102. Mohiuddin M, Regine WF, John WJ, et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys. 2000;46:883–8. · DOI · Paper page
  103. Pfeifer P. High-dose radiotherapy and concurrent UFT plus L-Leucovorin in locally advanced rectal cancer: a phase I trial. Acta Oncol. 2005;44:224–9. · doi:10.1080/02841860510029671
  104. Jakobsen A, Mortensen JP, Bisgaard C, et al. Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. Int J Radiat Oncol Biol Phys. 2006;64:461–5. · DOI
  105. Movsas B, Diratzouian H, Hanlon A, et al. Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer. Am J Clin Oncol. 2006;29:435–41. · doi:10.1097/01.coc.0000227480.41414.f2
  106. Freedman GM, Meropol NJ, Sigurdson ER, et al. Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2007;67:1389–93. · DOI
  107. El-Sayed M, EL-Taher ZH. Prospective phase II study of brachytherapy boost as a component of neo-adjuvant chemotherapy and external beam radiation therapy in locally advanced rectal cancer. J Egypt Nat Cancer Inst. 2008;20:10–6.
  108. Vestermark LW, Jacobsen A, Ovortrup C, et al. Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/L-leukocorin in patients with non-resectable locally advanced rectals cancer (LARC). Acta Oncol. 2008;47:428–33. · DOI
  109. Ballonoff A, Kavanagh B, McCarter M, et al. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol. 2008;31:264–70. · DOI
  110. Lindebjerg J, Spindler KL, Ploen J, Jakobsen A. The prognostic value of lymph node metastases and tumor regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy. Colorectal Dis. 2009;11:264–9. · DOI
  111. Marsh R, George TJ, Siddiqui T, et al. A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer. Am J Clin Oncol. 2010;33:251–6. · DOI
  112. Maluta S, Romano M, Dall’oglio S, et al. Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum. Int J Hyperthermia. 2010;26:108–77. · DOI
  113. Arbea L, Martinez-Monge R, Diaz-Gonzalez JA, et al. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine an oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. Int J Radiat Oncol Biol Phys. 2012;83:587–93. · DOI
  114. Caravatta L, Padula GD, Picardi V, et al. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study. Acta Oncol. 2011;50:1151–7. · DOI
  115. Barsukov YA, Gordeyev SS, Tkachev SI, Fedyanin MY, Perevoshikov AG. Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer. Colorect Dis. 2013;15:1107–14. · DOI
  116. Caravatta L, Picardi V, Tambaro R, et al. Neodjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: a dose escalation study. Am J Clin Oncol. 2012;35:424–31. · DOI
  117. Li JL, Ji JF, Cai Y, et al. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phae II trial. Radiother Oncol. 2012;102:4–9. · DOI
  118. Jakobsen A, Ploen J, Vuong T, et al. Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys. 2012;84:949–54. · DOI
  119. Vestermark LW, Jensen HA, Pfeiffer P. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of Oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial. Acta Oncol. 2012;51:311–7. · DOI
  120. Zhu J, Liu F, Gu W, et al. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Radiat Oncol. 2014;9:70. · DOI
  121. Cubillo A, Hernando-Requejo O, Garcia-Garcia E, et al. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. Am J Clin Oncol. 2014;37:117–21. · DOI
  122. Hernando-Requejo O, Lopez M, Cubillo A, et al. Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation. Strahlenther Onkol. 2014;190:515–20. · DOI
  123. Appelt AL, Ploen J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27. · DOI · Paper page
  124. Omidvari S, Zohourinia S, Ansari M, et al. Efficacy and safety of low-dose-rate endorectal brachytherapy as a boost to neoadjuvant chemoradiation in the treatment of locally advanced distal rectal cancer: a phase-II clinical trial. Ann Coloproctol. 2015;31:123–30. · DOI
  125. But-Hadzic J, Anderluh F, Brecelj E, et al. Acute toxicity and tumor response in locally advanced rectal cancer after preoperative chemoradiation therapy with shortening of the overall treatment time using intensity-modulated radiation therapy with simultaneous integrated Boost: a phase 2 trial. Int J Radiat Oncol Biol Phys. 2016;96:1003–10. · DOI
  126. Picardi V, Deodato F, Guido A, et al. Concurrent chemoradiation with concomitant Boost in locally advanced rectal cancer: a phase II study. Anticancer Res. 2016;36:4081–8.
  127. Hall MD, Schultheiss TE, Smith D, et al. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy. Acta Oncol. 2016;55:1392–9. · DOI
  128. Picardi V, Macchia G, Guido A, et al. Preoperative chemoradiation with VMAT-SIB in rectal cancer: a phase II study. Clin Colorectal Cancer. 2016;16:16–22. · DOI
  129. Tey J, Leong CN, Cheong WK, et al. A phase II trial of preoperative concurrent chemotherapy and dose escalated intensity modulated radiotherapy (IMRT) for locally advanced rectal cancer. J Cancer. 2017;8:3114–21. · DOI
  130. Idasiak A, Galwas-Kliber K, Behrendt K, et al. Pre-operative hyperfractionated concurrent radiochemotherapy for locally advanced rectal cancers: a phase II clinical study. Br J Radiol. 2017;90:20160731. · DOI
  131. Alongi F, Fersino S, Mazzola R, et al. Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. Clin Transl Oncol. 2017;19:189–96. · DOI
  132. Gunther JR, Chadha AS, Shin US, et al. Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: a matched-pair analysis. Adv Radiat Oncol. 2017;2:455–64. · doi:10.1016/j.adro.2017.04.001
  133. Jalil O, Claydon L. Arulampam. Review of neoadjuvant chemotherapy alone in locally advanced rectal cancer. J Gastrointest Cancer. 2015;46:219–36. · DOI
  134. Chau I, Bown G, Cunningham D, et al. Neoadjuvant Capecitabine and Oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic-resonance imaging-defined poor-risk rectal cancer. J Clin Oncol. 2006;24:668–74. · DOI · Paper page
  135. Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and Oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:241–8. · DOI · Paper page
  136. Koeberle D, Burkhard R, von Moos R, et al. Phase II study of capecitabine and Oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer. 2008;98:1204–9. · DOI
  137. Zampino MG, Magni E, Leonardi MC, et al. Capecitabine initially concomitant to radiotherapy the preoperatively administered in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2009;75:421–7. · DOI
  138. Fernandez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capitabine and Oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de Recto 3 study. J Clin Oncol. 2020;28:859–65. · DOI · Paper page
  139. Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol. 2015;26:1722–8. · DOI · Paper page
  140. Nogue M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16:614–20. · DOI · Paper page
  141. Chiorean EG, Sanghani S, Schiel MA, et al. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capicitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. Cancer Chemother Pharmacol. 2012;70:25–32. · DOI
  142. Marechal R, Vos B, Polus M, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol. 2012;23:1525–30. · DOI · Paper page
  143. Zhu J, Gu W, Lian P, et al. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma. Radiat Oncol. 2013;8:130. · DOI
  144. Gao YH, Lin JZ, An X, et al. Neoadjuvant sandwich treatment with Oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase II trial. Int J Radiat Oncol Biol Phys. 2014;90:1153–60. · DOI
  145. Borg C, Andre T, Mantion G, et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized noncomparative phase II study. Ann Oncol. 2014b;25:2205–10. · DOI
  146. Marco MR, Zhou L, Patil S, et al. Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Col Rect. 2018;61:1146–55. · DOI · Paper page
  147. Bujko K, Wyrwicz L, Rutkowski A, et al. Long-course Oxaliplatin-based preoperative chemoradiation versus 5x5 Gy and consolidation chemotherapy fpr CT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27:834–42. · DOI · Paper page
  148. Perez K, Safran H, Sikov W, et al. Complete neoadjuvant treatment for rectal cancer: The Bronw university oncology group CONTRE study. Am J Clin Oncol. 2017;40:282–7. · DOI
  149. Cercek A, Campbell SD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4:e180071. · DOI · Paper page
  150. van der Valk MJ, Marijnen CA, van Etten B, et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high.risk rectal cancer—results of the international randomized RAPIDO-trial. Radiother Oncol. 2020;147:75–83. · DOI · Paper page
  151. Hospers G, Bahadoer RR, Dijkstra EA, et al. Short course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: the randomized RAPIDO trial (abstract). J Clin Oncol. 2020;38(suppl):4006. · doi:10.1200/jco.2020.38.15_suppl.4006
  152. Conroy T, Lamfichekh N, Etienne PL, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patiets with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, a UNICANCER GI trial (abstract). J Clin Oncl. 2020;38(suppl):4007. · doi:10.1200/jco.2020.38.15_suppl.4007
  153. Lefevre J, Mineur L, Cachanado M, et al. Does a longer waiting period after neoadjuvant radio-chemotherapy improve the oncological prognosis of rectal cancer ? Three years’ results of the GRECCAR-6 randomized multicenter trial. Ann Surg. 2019;270(747):753.
  154. Lezoche E, Baldarelli M, Lezoche G, et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg. 2012;99:1211–8. · DOI · Paper page
  155. Rullier E, Vendrely V, Asselineau J, et al. (2020) Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020;5:465–74. · DOI
  156. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7. · DOI · Paper page
  157. Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006;10:1319–28. · DOI · Paper page
  158. Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, van Dam RM, Jansen RL, Sosef M, Leijtens JW, Hulsewé KW, Buijsen J, Beets GL. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(5):4633–40. · DOI · Paper page
  159. Martens MH, Maas M, Heijnen LA, Lambregts DM, Leijtens JW, Stassen LP, Breukink SO, Hoff C, Belgers EJ, Melenhorst J, Jansen R, Buijsen J, Hoofwijk TG, Beets-Tan RG, Beets GL. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst. 2016;108(12):djw171. · DOI · Paper page
  160. Hupkens BJP, Martens MH, Stoot JH, Berbee M, Melenhorst J, Beets-Tan RG, Beets GL, Breukink SO. Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection—a matched-controlled study. Dis Colon Rectum. 2017;60(10):1032–40. · DOI · Paper page
  161. Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, Rooney PS, Susnerwala S, Blower A, Saunders MP, Wilson MS, Scott N, O’Dwyer ST. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17(2):174–83. · DOI · Paper page
  162. van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, Habr-Gama A, Perez RO, Renehan AG, van de Velde CJH; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537–45. · DOI · Paper page
  163. Dattani M, Heald RJ, Goussous G, Broadhurst J, São Julião GP, Habr-Gama A, Perez RO, Moran BJ. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg. 2018;268(6):955–67. · DOI · Paper page
  164. Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7):501–13. · DOI · Paper page
  165. Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum. 2013;56:1109–17. · DOI

Cited by

See all 77

Metadata

Authors
Roeder, F., Meldolesi, E., Gerum, S., Valentini, V., & Rödel, C.
Venue
Radiation Oncology
Published
2020-11-10
Volume
15
Issue
1
Pages
262-262
ISSN
1748-717X (ISSN-L)
OpenAlex
W3100677696
Cited by
77
References
9
FWCI
3.29
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review. https://app.cochat.ai/papers/10.1186/s13014-020-01695-0
The paper
Roeder, F., Meldolesi, E., Gerum, S., Valentini, V., & Rödel, C. (2020). Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review. Radiation Oncology. https://doi.org/10.1186/s13014-020-01695-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.